CN118369097A - 包含环丙沙星和塞来昔布的组合物 - Google Patents

包含环丙沙星和塞来昔布的组合物 Download PDF

Info

Publication number
CN118369097A
CN118369097A CN202280081257.7A CN202280081257A CN118369097A CN 118369097 A CN118369097 A CN 118369097A CN 202280081257 A CN202280081257 A CN 202280081257A CN 118369097 A CN118369097 A CN 118369097A
Authority
CN
China
Prior art keywords
tablet
ciprofloxacin
celecoxib
hours
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280081257.7A
Other languages
English (en)
Chinese (zh)
Inventor
阿隆·本·诺恩
杰弗里·斯德林
欧隆·亚科比·泽维
莎伦·科恩·韦雷德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuroinduction Therapy Co ltd
Original Assignee
Neuroinduction Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroinduction Therapy Co ltd filed Critical Neuroinduction Therapy Co ltd
Publication of CN118369097A publication Critical patent/CN118369097A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280081257.7A 2021-10-19 2022-10-18 包含环丙沙星和塞来昔布的组合物 Pending CN118369097A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163257130P 2021-10-19 2021-10-19
US63/257,130 2021-10-19
PCT/IL2022/051096 WO2023067592A1 (en) 2021-10-19 2022-10-18 Compositions comprising ciprofloxacin and celecoxib

Publications (1)

Publication Number Publication Date
CN118369097A true CN118369097A (zh) 2024-07-19

Family

ID=85982158

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280081257.7A Pending CN118369097A (zh) 2021-10-19 2022-10-18 包含环丙沙星和塞来昔布的组合物

Country Status (9)

Country Link
US (1) US12097185B2 (enExample)
EP (1) EP4419099A4 (enExample)
JP (1) JP7857044B2 (enExample)
KR (1) KR20240090519A (enExample)
CN (1) CN118369097A (enExample)
AU (1) AU2022370513B2 (enExample)
CA (1) CA3235348A1 (enExample)
IL (1) IL312274A (enExample)
WO (1) WO2023067592A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
EP3641820B1 (en) * 2017-06-20 2022-12-28 Neurosense Therapeutics Ltd. Compositions comprising an anti-inflammatory drug and a dicer activator for use in the treatment of neuronal diseases
US12527768B2 (en) * 2017-06-20 2026-01-20 Neurosense Therapeutics Ltd. Compositions comprising an anti-inflammatory drug and a dicer activator for use in the treatment of neuronal diseases

Also Published As

Publication number Publication date
US20230120880A1 (en) 2023-04-20
EP4419099A1 (en) 2024-08-28
US12097185B2 (en) 2024-09-24
IL312274A (en) 2024-06-01
CA3235348A1 (en) 2023-04-27
AU2022370513A1 (en) 2024-05-16
EP4419099A4 (en) 2025-09-24
AU2022370513B2 (en) 2025-09-25
KR20240090519A (ko) 2024-06-21
JP2024539116A (ja) 2024-10-28
JP7857044B2 (ja) 2026-05-12
WO2023067592A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
JP5808670B2 (ja) 弱塩基性薬物を含む組成物及び徐放性剤形
EP1441713B1 (en) Modified release tamsulosin tablets
JP3725542B2 (ja) ピコサルフェート剤形
AU2007338359B2 (en) Pharmaceutical formulation comprising neurokinin antagonist
SK285152B6 (sk) Enterický potiahnutý farmaceutický prostriedok a spôsob jeho prípravy
JP5597343B2 (ja) 抗痴呆薬を含有する組成物
US20090124702A1 (en) Pharmaceutical Compositions of Metformin
WO2022177983A1 (en) Pharmaceutical compositions of cabozantinib
TW201442742A (zh) 祛鐵斯若(deferasirox)之口服配方
CN102470109A (zh) 3-氰基喹啉片剂制剂及其应用
AU2013229990A1 (en) Controlled-release solid dosage forms of mesalamine
JP2015506337A (ja) 新規配合剤
JP2004067606A (ja) イトラコナゾール経口投与製剤
US20130344148A1 (en) Oral Composition
JPH05246861A (ja) ポリカルボフィルカルシウム含有製剤
WO2005027876A1 (en) Pharmaceutical compositions of benzimidazole and processes for their preparation
US20100280035A1 (en) Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a ph modifier
EP4486308A1 (en) Therapeutic compounds, formulations, and use thereof
AU2022370513B2 (en) Compositions comprising ciprofloxacin and celecoxib
JP2006507298A (ja) 経口持続放出型錠剤、ならびにその製造法および使用法
HK40113418A (zh) 包含环丙沙星和塞来昔布的组合物
BR112024007727B1 (pt) Composições que compreendem ciprofloxacina e celecoxibe
CZ2004235A3 (cs) Farmaceutická kompozice obsahující jako účinnou látku platinový komplex a způsob výroby této kompozice
EP4595955A1 (en) Compositions and methods for treating bile acid malabsorption
KR101428149B1 (ko) 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40113418

Country of ref document: HK